Emerging Hypervirulent Marek's Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines.

As one of the most important avian immunosuppressive and neoplastic diseases, Marek's disease (MD), caused by oncogenic Marek's disease virus (MDV), has caused huge economic losses worldwide over the past five decades. In recent years, MD outbreaks have occurred frequently in MD-vaccinated chicken flocks, but the key pathogenic determinants and influencing factors remain unclear. Herein, we analyzed the pathogenicity of seven newly isolated MDV strains from tumor-bearing chickens in China and found that all of them were pathogenic to chicken hosts, among which four MDV isolates, SDCW01, HNXZ05, HNSQ05 and HNSQ01, were considered to be hypervirulent MDV (HV-MDV) strains. At 73 days of the virus infection experiment, the cumulative incidences of MD were 100%, 93.3%, 90% and 100%, with mortalities of 83.3%, 73.3%, 60% and 86.7%, respectively, for the four viruses. The gross occurrences of tumors were 50%, 33.3%, 30% and 63.3%, respectively, accompanied by significant hepatosplenomegaly and serious atrophy of the immune organs. Furthermore, the immune protection effects of four commercial MD vaccines against SDCW01, CVI988, HVT, CVI988+HVT, and 814 were explored. Unexpectedly, during the 67 days of post-virus challenge, the protection indices (PIs) of these four MD vaccines were only 46.2%, 38.5%, 50%, and 28%, respectively, and the birds that received the monovalent CVI988 or HVT still developed tumors with cumulative incidences of 7.7% and 11.5%, respectively. To our knowledge, this is the first demonstration of the simultaneous comparison of the immune protection efficacy of multiple commercial MD vaccines with different vaccine strains. Our study revealed that the HV-MDV variants circulating in China could significantly break through the immune protection of the classical MD vaccines currently widely used. For future work, there is an urgent need to develop novel, more effective MD vaccines for tackling the new challenge of emerging HV-MDV strains or variants for the sustainable control of MD.

Effects of the Methionine Hydroxyl Analogue Chelate Zinc on Antioxidant Capacity and Liver Metabolism Using 1H-NMR-Based Metabolomics in Aged Laying Hens.

This study aimed to investigate the effects of different levels of methionine hydroxyl analogue chelated zinc (MHA-Zn) on antioxidant capacity and liver metabolism of aged laying hens. A total of 960 57-week-old layers were fed a basal diet (Zn: 35.08 mg/kg) without extra zinc for two weeks, and then allocated to four treatments consisting of eight replicates of 30 birds each for 14 weeks. Four levels of Zn (zinc sulfate (ZnSO4): 80 mg/kg; MHA-Zn: 20, 40, 80 mg/kg) were added to the diet. The results indicated that compared with inorganic zinc, organic zinc of 80 mg/kg has a significant advantage in improving the antioxidant capacity of aged hens, which increased the level of Cu/Zn-superoxide dismutase (SOD) and the total antioxidant capacity (T-AOC) in the serum and liver, and reduced the concentration of malondialdehyde (MDA) of laying hens. The serum albumen composition was significantly modified, meanwhile, the level of total protein, globulin, and urea increased remarkably, whereas serum glutamic-oxaloacetic transaminase decreased notably in 80 mg/kg MHA-Zn groups. Compared with the 20 mg/kg MHA-Zn group, the metabolic profile of 40 and 80 mg/kg MHA-Zn groups was higher than that of the inorganic zinc group. Furthermore, integrated key metabolic pathway analysis showed that 40 and 80 mg/kg MHA-Zn groups participated in the regulation of glutathione metabolism, glycine, serine, and threonine metabolism. Therefore, this study suggests that 40 and 80 mg/kg supplementation of MHA-Zn can increase the activity of Cu/Zn-SOD and T-AOC and decrease MDA; additionally the 80 mg/kg MHA-Zn group has better antioxidant capacity. Meanwhile, the enhanced MHA-Zn promoted methionine (Met) synthesis and protein metabolism.

Effects of Dietary Threonine Levels on Intestinal Immunity and Antioxidant Capacity Based on Cecal Metabolites and Transcription Sequencing of Broiler.

This study aimed to determine the effects of different dietary threonine levels on the antioxidant and immune capacity and the immunity of broilers. A total of 432 one-day-old Arbor Acres (AA) broilers were randomly assigned to 4 groups, each with 6 replicates of 18 broilers. The amount of dietary threonine in the four treatments reached 85%, 100%, 125%, and 150% of the NRC (Nutrient Requirements of Poultry, 1994) recommendation for broilers (marked as THR85, THR100, THR125, and THR150). After 42 days of feeding, the cecum contents and jejunum mucosa were collected for metabolic analysis and transcriptional sequencing. The results indicated that under the condition of regular and non-disease growth of broilers, compared with that of the THR85 and THR150 groups, the metabolic profile of the THR125 group was significantly higher than that of the standard requirement group. Compared with the THR100 group, the THR125 group improved antioxidant ability and immunity of broilers and enhanced the ability of resisting viruses. The antioxidant gene CAT was upregulated. PLCD1, which is involved in immune signal transduction and plays a role in cancer suppression, was also upregulated. Carcinogenic or indirect genes PKM2, ACY1, HK2, and TBXA2 were down-regulated. The genes GPT2, glude2, and G6PC, which played an important role in maintaining homeostasis, were up-regulated. Therefore, the present study suggests that 125% of the NRC recommendations for Thr level had better effects on antioxidant and immune capacity, as well as maintaining the homeostasis of the body.

A deficient or an excess of dietary threonine level affects intestinal mucosal integrity and barrier function in broiler chickens.

The aim of this study was to investigate the effects of deficient or excess of dietary threonine (Thr) levels on intestinal integrity and barrier function of broilers. A total of 432 1-day-old commercial broilers (Arbor Acre) were assigned to four experiment groups consisting of six replicates of 18 birds. The treatments were designed as follows: 85%, 100%, 125% and 150% of NRC (Nutrient requirements of poultry (9th edn). Washington, DC: The National Academies Press, 1994) recommendations. The results indicated that expressions of jejunal and ileal secretory immunoglobulin A (sIgA) mRNA were increased linearly or quadratically by increasing Thr (p < .05), and the highest sIgA mRNA abundance was obtained in 125% Thr level. Likewise, the intestinal sIgA content showed similar increasing trend with the intestinal sIgA gene expression in this instance. The high level of Thr inclusion upregulated mucin 2 (MUC2) mRNA expression in the jejunum and ileum (p < .05). In addition, on day 21, the expression levels of jejunal zonula occludens-2 (ZO-2) and ileal zonula occludens-1 (ZO-1) decreased then increased with increasing Thr level (p < .05), whereas, the mRNA expressions of occludin in the jejunum and ileum had no significant difference amongst groups (p >.05). On day 42, Thr treatments did not affect the mRNA abundance of measured genes in the jejunum and ileum (p > .05). These findings suggested that Thr might be a nutrient immunomodulator that affects intestinal barrier function, moreover, 125% of the NRC (1994) recommendations Thr level was optimum.